Skip to content

Darunavir/ritonavir superior virologically and immunologically to comparator drugs over one year

Two-class ART just as good as three-class in the long-term, and has fewer side-effects

Brain problems and peripheral neuropathy under-diagnosed in Asia and the Pacific

Duration of HIV infection and duration of HIV therapy use risk factors for bone disease

Genetics associated with risk of severe allergic reaction to nevirapine

Lowered AZT dose for low weight patients 'effective and reduces toxicity'

NRTI-sparing combination of ritonavir-boosted indinavir and efavirenz improves fat loss but worsens blood fat and sugar levels

Deep vein thrombosis risk increases as HIV disease worsens

Direct link found between early sign of cardiovascular disease risk and AZT, possibly other NRTIs